Parallax Volatility Advisers, L.P. Madrigal Pharmaceuticals, Inc. Call Options Transaction History

Parallax Volatility Advisers, L.P.

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$193.33 - $291.99 $5.07 Million - $7.65 Million	26,200 Added 1091.67%	28,600 $8.01 Million
Q1 2024 May 15, 2024	SELL	$171.37 - $283.23 $445,562 - $736,398	-2,600 Reduced 52.0%	2,400 $640,000
Q3 2023 Nov 14, 2023	SELL	$146.04 - $225.78 $14,604 - $22,578	-100 Reduced 1.96%	5,000 $730,000
Q2 2023 Aug 14, 2023	SELL	$203.88 - $312.0 $5 Million - $7.64 Million	-24,500 Reduced 82.77%	5,100 $1.18 Million
Q1 2023 May 15, 2023	SELL	$231.06 - $307.08 $11.1 Million - $14.8 Million	-48,100 Reduced 61.9%	29,600 $7.17 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $4.54 Million - $23 Million	77,700 New	77,700 $22.6 Million
Q2 2019 Aug 14, 2019	SELL	$91.13 - $142.5 $5.56 Million - $8.69 Million	-61,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$207.3 - $300.31 $12.6 Million - $18.3 Million	61,000 New	61,000 $13.1 Million

296

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.94B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.